Streetbeat News

ELVN

Enliven Therapeutics, Inc.

https://www.enliventherapeutics.com

Industry

Biotechnology

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Peraso Inc. reported worse-than-expected Q4 EPS results, causing its shares to fall by over 23%. Other stocks experienced significant movements, with notable gainers including Ontrak, Fusion Pharmaceuticals, and Spire Global, among others. Losers included Greenwave Technology Solutions, Seelos Therapeutics, and Comtech Telecommunications, with various reasons such as disappointing financial results, downgrades, and restructuring of debt.

Portfolio Pulse from Avi Kapoor

March 19, 2024 | 5:48 pm

The article reports on significant intraday movements of health care stocks, highlighting both gainers and losers. Ontrak, Fusion Pharmaceuticals, and SCWorx led the gainers with substantial increases in their stock prices, while Acutus Medical, Seelos Therapeutics, and Lantern Pharma were among the top losers. Notably, Enliven Therapeutics, Lantern Pharma, Eyenovia, and Acurx Pharmaceuticals had recent Q4 earnings reports influencing their stock movements.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 5:31 pm

National CineMedia, Inc. (NCMI) reported strong Q4 results and announced a $100 million share repurchase program, leading to a 25.5% stock increase. Other stocks like Fusion Pharmaceuticals (FUSN), Spire Global (SPIR), and Zoomcar Holdings (ZCAR) also saw significant gains due to various positive developments. Notably, Fusion Pharmaceuticals is being acquired by AstraZeneca, and Spire Global announced a collaboration with NVIDIA.

Portfolio Pulse from Avi Kapoor

March 19, 2024 | 2:03 pm

Enliven Therapeutics' stock is trading higher following the announcement of a $90 million private placement financing and updates on its pipeline.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 1:10 pm

In Tuesday's pre-market session, several healthcare stocks showed significant movement. Ontrak, Fusion Pharmaceuticals, and Enveric Biosciences were among the top gainers, with Ontrak leading at a 173.2% increase. Conversely, Seelos Therapeutics, Acurx Pharmaceuticals, and Motus GI Holdings were the top losers, with Seelos Therapeutics dropping by 42.7%. These movements reflect the volatile nature of healthcare stocks and could be influenced by recent earnings reports and market capitalization changes.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 1:05 pm

Enliven Therapeutics announced a $90M private placement financing, with participation from new and existing investors. The net proceeds are expected to extend the company's cash runway into late 2026, supporting key clinical milestones for ELVN-001 and ELVN-002. An event with KOLs is scheduled for April 11, 2024, to discuss Phase 1a trial data of ELVN-001 in adults with chronic myeloid leukemia.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 12:36 pm

Enliven Therapeutics reported Q4 earnings with losses of $(0.47) per share, surpassing the consensus estimate of $(0.54) by 12.96%. This marks a significant increase in losses compared to the $(0.08) per share from the same quarter last year.

Portfolio Pulse from Happy Mohamed

March 14, 2024 | 8:15 pm

In Monday's after-market session, several health care stocks showed significant movement. Janux Therapeutics, ICU Medical, and Galera Therapeutics were among the top gainers, with Janux Therapeutics leading at a 64.2% increase. On the losing end, NRX Pharmaceuticals saw the largest decrease at 20.5%. The movements were largely attributed to the release of Q4 earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 9:31 pm

In Tuesday's after-market session, several healthcare stocks experienced significant movements. Moleculin Biotech, Evoke Pharma, TC BioPharm, CNS Pharma, Atreca, and ASLAN Pharma were among the gainers, with increases ranging from 5.94% to 8.7%. Conversely, Savara, MyMD Pharmaceuticals, Alector, Enliven Therapeutics, Estrella Immunopharma, and Trevena were the losers, with declines between 4.97% and 11.9%. The market capitalizations of these companies vary, with some below $10 million and others exceeding $500 million.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 9:31 pm

Enliven Therapeutics reported Q3 losses of $(0.51) per share, missing the analyst consensus estimate of $(0.47) by 8.51 percent. This is a 29.17 percent increase over losses of $(0.72) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:29 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.